Literature DB >> 1860680

A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients.

A Gatta1, P Angeli, L Caregaro, F Menon, D Sacerdoti, C Merkel.   

Abstract

It has been hypothesized that the magnitude of proximal sodium reabsorption affects the response to aldosterone antagonists in nonazotemic cirrhotic patients with ascites. To verify this hypothesis, we evaluated intrarenal sodium handling by lithium clearance in 51 nonazotemic ascitic cirrhotic patients and in 23 controls who were maintained on the same low-sodium diet (80 mmol/day). Seven of 51 cirrhotic patients underwent spontaneous diuresis, whereas 44 required diuretic treatment. Treatment was started with spironolactone at a dose of 150 mg once daily. The dose was increased to 300 mg and then to 500 mg once daily if no response ensued. Cirrhotic patients who did not experience ascites mobilization with 500 mg spironolactone were then treated with a combined diuretic regimen that included spironolactone at a fixed dose (500 mg once daily) and furosemide at an initial dose of 50 mg once daily. The dose was increased to 100, 150 and 200 mg once daily if no response was noticed. Response to diuretic treatment was defined as body weight loss greater than 700 gm every 3 days until ascites became clinically undetectable. Nonresponders (43%) to spironolactone showed lower sodium fractional excretion (0.34% +/- 0.28% vs. 0.80% +/- 0.50%; p less than 0.001) because of a lower fractional sodium delivery to the distal tubule (18.2% +/- 5.8% vs. 23.4% +/- 7.2%; p less than 0.025) than responders.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1860680

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  13 in total

1.  Guidelines on the management of ascites in cirrhosis.

Authors:  K P Moore; G P Aithal
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

Review 2.  Management of ascites and hepatorenal syndrome.

Authors:  Salvatore Piano; Marta Tonon; Paolo Angeli
Journal:  Hepatol Int       Date:  2017-08-23       Impact factor: 6.047

3.  Loss of tubuloglomerular feedback in decompensated liver cirrhosis: physiopathological implications.

Authors:  Giovanni Sansoè; Stefano Silvano; Giulio Mengozzi; Antonina Smedile; Giovanni Touscoz; Floriano Rosina; Mario Rizzetto
Journal:  Dig Dis Sci       Date:  2005-05       Impact factor: 3.199

4.  Diagnosis and therapy of ascites in liver cirrhosis.

Authors:  Erwin Biecker
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

5.  Renal tubular events following passage from the supine to the standing position in patients with compensated liver cirrhosis: loss of tubuloglomerular feedback.

Authors:  G Sansoè; A M Biava; S Silvano; A Ferrari; F Rosina; A Smedile; A Touscoz; L Bonardi; M Rizzetto
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

Review 6.  Pharmacotherapy of ascites associated with cirrhosis.

Authors:  P Ginès; V Arrovo; J Rodés
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

7.  Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study.

Authors:  Shweta Bansal; David Badesch; Todd Bull; Robert W Schrier
Journal:  Contemp Clin Trials       Date:  2009-04-16       Impact factor: 2.226

8.  Management of renal failure and ascites in patients with cirrhosis.

Authors:  Kaushal Madan; Ashish Mehta
Journal:  Int J Hepatol       Date:  2011-09-27

9.  The Impact of Outpatient Clinical Care on the Survival and Hospitalisation Rate in Patients with Alcoholic Liver Cirrhosis.

Authors:  Dejan Majc; Bojan Tepes
Journal:  Radiol Oncol       Date:  2017-12-07       Impact factor: 2.991

10.  Preclinical study of simultaneous pharmacokinetic and pharmacodynamic herb-drug interactions between Yin-Chen-Hao-Tang and spironolactone.

Authors:  Tun-Pin Hsueh; Tung-Hu Tsai
Journal:  BMC Complement Med Ther       Date:  2020-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.